Mark S. MD Gelder - Feb 7, 2022 Form 4 Insider Report for Onconova Therapeutics, Inc. (ONTX)

Role
Chief Medical Officer
Signature
/s/ Mark Guerin as attorney-in-fact
Stock symbol
ONTX
Transactions as of
Feb 7, 2022
Transactions value $
$0
Form type
4
Date filed
2/9/2022, 03:52 PM
Previous filing
Sep 29, 2021
Next filing
Aug 4, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ONTX Stock Option (right to purchase) Award $0 +51.8K $0.00 51.8K Feb 7, 2022 Common stock 51.8K $1.82 Direct F1
transaction ONTX Restricted Stock Units Award $0 +17.5K $0.00 17.5K Feb 7, 2022 Common stock 17.5K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.
F2 These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.
F3 Each restricted stock unit is convertible into one share of common stock.